Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY／Most Mainstay Products Avoid Deep Price Cuts in FY2008 NHI Price Revision
March 31, 2008
- Methodologic Issues in the Clinical Trial Study of Depression
March 24, 2008
- COMMENTARY／Major Wholesalers vs Hansha Competition to Intensify on Growing Market for Generics
March 3, 2008
- COMMENTARY／Preparations for New OTC Drug Marketing System Enter Final Stage
March 3, 2008
- COMMENTARY／Japan Needs to Create Attractive "Stadium for Drug Discovery" and Invite Top-Level Players
February 25, 2008
- Current New Drug Development in the Japanese Pharmaceutical Industry（1）
February 11, 2008
- COMMENTARY／Revision of Medical Fees May Increase Use of Drugs for Stroke, Mental Illnesses, Cancer
February 11, 2008
- Current New Drug Development in the Japanese Pharmaceutical Industry（2）
February 11, 2008
- COMMENTARY／Generic Makers Increase Investment, but Will Consumption Really Increase as Gov't Hopes？
February 4, 2008
- COMMENTARY／Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
- OPINION／The East versus West Dilemma
January 28, 2008
- COMMENTARY／Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
- No More Need for MRs？ -A Hell beyond the 2010 Crisis？-
January 14, 2008
- COMMENTARY／Year 2007 in Retrospect
December 24, 2007
- COMMENTARY／Appreciation Mixed with Concern: Proposed NHI Pricing Reform
December 17, 2007
- COMMENTARY／Fight over Medical Fee/NHI Price Revision Rates Begin
December 3, 2007
- COMMENTARY：Korosho Must Explain Its "Primary Doctor" System Proposal in Detail
October 1, 2007
- Gakkai, Specialty Certification and Industry by Mark Colby
September 10, 2007
- COMENTARY：Korosho Required to Cut \220 Bil. in Social Security Spending
September 3, 2007
- COMMENTARY／NHI Drug Pricing System Reform: Many Similarities in Proposals from JPMA, PhRMA, EFPIA
August 27, 2007
ページ
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…